Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs.
about
Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation.Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formationIdentification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic EnzymesDegradation and Stabilization of Peptide Hormones in Human Blood SpecimensInterrogating the Venom of the Viperid Snake Sistrurus catenatus edwardsii by a Combined Approach of Electrospray and MALDI Mass Spectrometry[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro.Identification of a novel insect neuropeptide, CNMa and its receptor.Survey of the year 2000 commercial optical biosensor literature.Characterization of lacrimal proline-rich protein 4 (PRR4) in human tear proteome.Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.Recombinant glucagon: a differential biological activity.Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells.Characterization of the post-translational modification of recombinant human BMP-15 mature protein.Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promiseInhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.Fibroblast growth factor 21 mediates specific glucagon actionsMolecular characterization of tick salivary gland glutaminyl cyclase.Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting.The New Biology and Pharmacology of Glucagon.CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry.Development of a high-throughput UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma.Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in miceA potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification.Differential regional metabolism of glucagon in anesthetized pigs.Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs.CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.Plant non-starch polysaccharides that inhibit key enzymes linked to type 2 diabetes mellitus.
P2860
Q24290340-8493BEF3-5093-45E3-B25B-5158B3342E09Q24532111-AF568B8A-2F80-4FCC-92F0-E1771BCE2FA5Q27642932-DBCDE751-CE61-4648-B571-762F141B022BQ28468557-E01DF5F5-DA08-4719-9356-189CA2C0E6C3Q28546842-77EF46D2-1AE2-49C0-8813-482179E0D47DQ28547112-A90EB829-294D-4A75-84B2-DBDC79AA23F6Q33194892-CEFEB649-1BA8-4D63-A31F-20E74726B5D8Q34100605-62298C47-57CB-4973-87AA-3459A4F9FADFQ34412693-88C37247-3CD9-4500-B84D-E4BE8DD77B6DQ34418835-55CA2A6A-6E2A-4538-AC35-FAB6C1772282Q34464911-320E8644-53C0-46D4-9E07-D728977200DAQ35159933-6D8CA6CB-650C-4500-9728-C0116C1D8D1CQ35189265-F4CC45D8-E0A8-43B8-99E0-43490471D0D7Q35266434-E69C3FEC-1DBA-427B-8481-6362242A169DQ35723683-F14228A7-E67B-48A7-8CAD-2BFFA58F1AEDQ36420046-7A9F18C0-0BDA-4F93-B40F-4E22AF990511Q36514704-7166A388-9707-4711-8BFD-36C5FC2EC27AQ36580608-7986F5A4-BB4B-4826-84D7-245FA36F0B9EQ36796145-2885C68E-F35F-427C-B034-E95A1BB087DEQ37086364-59C20378-2310-4F12-990E-38E84971EB60Q37362688-6F87095F-44D0-428B-A8C5-194BF0F915C9Q38919742-F77E0050-0C73-421D-8112-46F9B619CFC4Q40710017-CCC72232-F987-405D-BD79-82CCAA6251EBQ41656530-A0B278EA-8AEB-4ED2-9913-C4C392D03F9CQ41982493-2CF11791-BEB5-4E56-B458-080BE2055A7DQ42704926-A9675F6D-0B61-4D82-8777-8E7CF1E86CA9Q44448756-5E05522A-5AB1-4A03-A318-2F2EB6BB0C6FQ44883020-C0A8B7FF-AC9C-453E-82D9-D0B5FCF5687AQ45996397-67C43FF1-7A63-418C-AB1F-3F485406F4E6Q50168668-76CBB4FC-5F4F-4CB5-A542-8247A5BBE2AF
P2860
Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Dipeptidyl peptidase IV (DPIV/ ...... ts and DPIV-resistant analogs.
@ast
Dipeptidyl peptidase IV (DPIV/ ...... ts and DPIV-resistant analogs.
@en
type
label
Dipeptidyl peptidase IV (DPIV/ ...... ts and DPIV-resistant analogs.
@ast
Dipeptidyl peptidase IV (DPIV/ ...... ts and DPIV-resistant analogs.
@en
prefLabel
Dipeptidyl peptidase IV (DPIV/ ...... ts and DPIV-resistant analogs.
@ast
Dipeptidyl peptidase IV (DPIV/ ...... ts and DPIV-resistant analogs.
@en
P2093
P2860
P356
P1476
Dipeptidyl peptidase IV (DPIV/ ...... ts and DPIV-resistant analogs.
@en
P2093
Hoffmann T
Kühn-Wache K
Mannhart S
McIntosh CH
Nishimura E
Pederson RA
Pospisilik JA
P2860
P304
P356
10.1074/JBC.275.6.3827
P407
P577
2000-02-01T00:00:00Z